A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer

The purpose of this study is to find a safe dose of investigational study drug, JNJ- 95298177 when given in combination with investigational drug, JNJ-78278343 in patients with prostate cancer. JNJ-78278343 and JNJ-95298177 are not approved by the United States Food and Drug Administration (FDA). The sponsor, Janssen Research & Development, provides the investigational study treatment, called “JNJ-78278343 and JNJ-95298177”. This is the first time that JNJ-78278343 is being used in combination with JNJ-95298177.

Are you Eligible? (Inclusion Criteria)

• At the time of informed consent, be ≥ 18 years of age 2. Must have metastatic castration-resistant prostate cancer (mCRPC) 3. Be willing and able to adhere to the lifestyle restrictions specified in the protocol.